ORAL KETOTIFEN

Mast Cell Stabilizer · H1 Antihistamine · Compounded Capsules

Prescriber Reference Guide · The Medicine Shoppe, York PA

MCAS · Histamine Intolerance · Mast Cell Disorders · Non-Commercially Available · Custom Dose

Program Overview

Oral ketotifen is a mast cell stabilizer and second-generation H1 antihistamine with a dual mechanism unavailable in any other single agent. It is not FDA-approved or commercially available in the United States -- compounding is the only legal source for oral capsules. For patients with mast cell activation syndrome (MCAS), histamine intolerance, or related mast cell disorders, compounded ketotifen allows precise dose titration starting at sub-milligram doses, using excipient-free formulations appropriate for chemically sensitive patients.

Key Clinical Advantages

- Dual mechanism -- mast cell stabilization upstream + H1 receptor blockade downstream; no other single agent provides both
- Compounding is the only US source -- oral ketotifen is not FDA-approved or commercially available domestically; The Medicine Shoppe compounds from USP-grade raw material
- Precise low-dose titration -- MCAS patients often require 0.25 mg starting doses; commercial formulations do not exist at these strengths
- Excipient-free formulation available -- critical for chemically sensitive patients who react to dyes, fillers, and binders in standard capsules
- Non-controlled -- no DEA scheduling, no prescribing restrictions, no prior authorization
- Long clinical history -- used internationally for MCAS and allergic conditions for decades; well-characterized safety and tolerability profile

Pathophysiology -- Mast Cell Activation Syndrome

MCAS is characterized by abnormal mast cell activation and mediator release in the absence of clonal mast cell disease (as in systemic mastocytosis). Mast cells in MCAS degranulate in response to a wide range of triggers -- foods, environmental exposures, physical stimuli, infections, stress -- releasing histamine, prostaglandins, leukotrienes, tryptase, cytokines, and other vasoactive and pro-inflammatory mediators. The resulting clinical syndrome is multi-system and highly variable, making diagnosis and treatment challenging.

Mast Cell Triggers	Foods (histamine-rich or liberating), medications, temperature changes, physical pressure, infections, hormonal fluctuations, emotional stress, and idiopathic triggers -- often highly individual
Mediators Released	Histamine, tryptase, prostaglandin D2, leukotriene C4, heparin, PAF, TNF-alpha, IL-6, and numerous other vasoactive and pro-inflammatory substances
Multi-System Impact	GI (cramping, nausea, diarrhea, GERD), dermatologic (urticaria, flushing, dermatographism), cardiovascular (palpitations, POTS, hypotension), neurological (brain fog, headache, anxiety), respiratory (bronchospasm, nasal congestion)

Histamine Intolerance	A related condition in which impaired histamine degradation (DAO/HNMT deficiency) leads to systemic histamine excess -- overlapping symptoms and treatment approach with MCAS
Diagnostic Criteria	Modified Molderings criteria: compatible symptoms in 2+ organ systems + response to anti-mediator therapy + elevated mast cell mediators (serum tryptase, urine histamine metabolites, prostaglandins) during or after reaction

Mechanism of Action

Ketotifen's clinical utility in MCAS derives from two synergistic pharmacological properties that address mast cell pathophysiology at distinct points in the activation cascade.

1. Mast Cell Stabilization (Upstream)

Mechanism	Ketotifen inhibits mast cell degranulation by blocking calcium influx and stabilizing the mast cell membrane. This prevents release of preformed mediators (histamine, tryptase, heparin) and newly synthesized mediators (prostaglandins, leukotrienes) in response to IgE-dependent and IgE-independent triggers.
Clinical Relevance	Stabilization acts upstream of mediator release -- unlike antihistamines, which only block histamine after it has been released. For MCAS patients with high mediator burden and frequent reactions, stabilization addresses the underlying pathophysiology rather than just blocking downstream effects.
Mechanism Comparison	Standard antihistamines: block H1/H2 receptors after histamine release. Cromolyn sodium: also a mast cell stabilizer but with poor oral bioavailability and primarily topical/GI use. Ketotifen: oral mast cell stabilizer with systemic distribution and concurrent H1 blockade -- the only agent providing both systemically.
Onset of Stabilization	Mast cell stabilization benefits typically require consistent use over 4-12 weeks to manifest fully -- patients must be counseled that this is not a PRN medication and that early sedation is expected to diminish.

2. H1 Antihistamine Activity (Downstream)

Mechanism	Second-generation H1 receptor inverse agonist -- blocks histamine binding at H1 receptors and stabilizes the receptor in its inactive conformation, reducing baseline receptor activity. Provides immediate symptomatic relief from histamine-mediated symptoms.
Sedation Profile	Ketotifen is more sedating than modern second-generation antihistamines (cetirizine, loratadine) due to CNS penetration. Sedation typically diminishes after 1-2 weeks as tolerance develops. Evening or bedtime initial dosing minimizes functional impact.
H1 vs. H2	Ketotifen provides H1 blockade; many MCAS patients require concurrent H2 blockade (famotidine, cimetidine) for GI symptoms. Prescribers should consider whether H2 coverage is adequate in the overall regimen.
Additional Properties	Anti-PAF (platelet-activating factor) activity; inhibits eosinophil chemotaxis; some evidence for mast cell tryptase inhibition -- broadening activity beyond pure H1 blockade

Clinical Evidence & Indications

MCAS	Ketotifen is among the most commonly prescribed mast cell stabilizers in MCAS management, supported by extensive clinical experience, patient registry data, and case series. Recommended in expert consensus guidelines (Afrin, Molderings) as a first- or second-line stabilizer.
Histamine Intolerance	Addresses both the H1 receptor-mediated symptoms and the underlying mast cell reactivity contributing to systemic histamine burden. Often used in combination with DAO enzyme supplementation and dietary histamine restriction.
Allergic Rhinitis / Urticaria	International evidence base for allergic conditions; approved and used for decades in Canada, Europe, and elsewhere. Chronic urticaria evidence supports ketotifen comparable to or exceeding cetirizine in some studies.
GI Mast Cell Involvement	Evidence for benefit in mast cell-mediated GI disorders, including IBS with mast cell infiltration, eosinophilic GI disorders, and MCAS with predominant GI manifestations. Oral delivery ensures GI tissue exposure.
Mastocytosis (Adjunct)	Used as adjunctive therapy in systemic mastocytosis for symptom control; not a primary disease-modifying treatment but contributes meaningfully to mediator symptom burden reduction.
Pediatric Use	Ketotifen ophthalmic is FDA-approved; oral ketotifen has an extensive pediatric safety record internationally (used for asthma prophylaxis in children in many countries). Compounding enables weight-based pediatric dosing.

Dosing & Titration Protocol

Titration is critical in MCAS patients. Starting too high causes intolerable sedation and discontinuation. A slow upward titration allows CNS tolerance to develop while mast cell stabilization builds. The following represents a standard protocol; individualize based on patient response and tolerability.

Starting Dose	0.25 mg orally once daily at bedtime for 1-2 weeks -- begin low to minimize initial sedation and allow assessment of tolerability
Titration Step 1	Increase to 0.25 mg twice daily (morning and evening) after 1-2 weeks if well tolerated
Titration Step 2	Increase to 0.5 mg twice daily after an additional 1-2 weeks
Target Maintenance	1 mg twice daily (2 mg/day total) is the most commonly used maintenance dose for MCAS; some patients achieve adequate control at lower doses
Maximum Dose	Up to 2 mg twice daily (4 mg/day) in patients with inadequate response at standard doses; titrate gradually
Timing	Bedtime dosing for the initial dose minimizes sedation impact; once twice-daily dosing begins, morning + evening is standard
Onset of Benefit	H1 antihistamine effects: immediate. Mast cell stabilization effects: 4-12 weeks of consistent use. Counsel patients explicitly that full benefit requires time -- early discontinuation due to sedation or perceived inefficacy is common and preventable.
Reassessment	Assess symptom burden, trigger threshold, and tolerability at 6-8 weeks; most patients require 3 months to fully evaluate stabilization benefit

Important Prescribing Notes

- Sedation counseling is essential -- warn all patients about initial drowsiness; most tolerate well after 1-2 weeks. Failure to counsel proactively is the leading cause of early discontinuation.
- This is NOT a PRN medication -- ketotifen must be taken consistently for mast cell stabilization to develop. Intermittent use provides only H1 antihistamine benefit and may prevent stabilization from occurring.
- Do not abruptly discontinue -- taper when stopping; abrupt discontinuation after prolonged use may cause rebound mast cell activation in some patients.
- CNS depression interactions -- additive sedation with alcohol, benzodiazepines, opioids, and other CNS depressants. Counsel patients explicitly.
- Concurrent H2 blocker -- most MCAS protocols include both H1 and H2 coverage; assess whether famotidine or similar is needed in the full regimen.

Drug Interactions & Contraindications

CNS Depressants	Additive sedation with alcohol, benzodiazepines, opioids, sleep aids, muscle relaxants, and other sedating antihistamines. Counsel patients and adjust timing if combining.
Anticholinergics	Additive anticholinergic effects (dry mouth, urinary retention, constipation, blurred vision). Use with caution in patients on anticholinergic medications or with BPH, narrow-angle glaucoma.
Oral Hypoglycemics	Case reports of thrombocytopenia with concurrent oral antidiabetic agents (sulfonylureas). Monitor platelet count if combining; not an absolute contraindication but warrants awareness.
MAO Inhibitors	Limited interaction data; general caution with concurrent MAOI use as with most antihistamines.
Contraindications	Hypersensitivity to ketotifen; caution in seizure disorders (lowered seizure threshold reported at higher doses); caution in urinary retention, BPH, narrow-angle glaucoma.
Pregnancy / Lactation	Limited human data; use only if benefit outweighs risk. Not recommended during breastfeeding due to potential infant sedation.

MCAS Regimen Context

Ketotifen is typically one component of a comprehensive MCAS management regimen. Prescribers should consider the full protocol when initiating ketotifen:

First Line	Second Line	Adjuncts
H1 antihistamine (non-sedating) H2 blocker (famotidine) Trigger avoidance Low-histamine diet if indicated	**Ketotifen (mast cell stabilizer)** Cromolyn sodium (GI-targeted) Leukotriene inhibitors (montelukast)	DAO enzyme supplement Aspirin/NSAID (PGD2 blockade) Vitamin C (histamine degradation) Epinephrine auto-injector (anaphylaxis risk)

Monitoring Recommendations

Baseline	Symptom inventory across affected organ systems (GI, skin, cardiovascular, neurological); document current antihistamine regimen; CBC if clinically indicated (thrombocytopenia monitoring with concurrent oral hypoglycemics)
2-4 Weeks	Assess sedation tolerance; confirm patient is dosing consistently (not PRN); address any early GI side effects (nausea uncommon but possible)
6-8 Weeks	Review symptom burden -- H1 benefits should be apparent; stabilization may still be building; assess trigger threshold changes
3 Months	Formal symptom reassessment; adjust dose upward if partial response; evaluate whether concurrent regimen adjustments are needed
Ongoing	Annual CBC if on concurrent oral hypoglycemics; regular reassessment of overall MCAS regimen; consider dose reduction trials in well-controlled patients after 12+ months
Epinephrine Access	Confirm patients at anaphylaxis risk have an epinephrine auto-injector regardless of ketotifen -- ketotifen reduces reactivity but does not eliminate anaphylaxis risk

Formulation & Dispensing

Dosage Form	Oral capsules -- compounded at The Medicine Shoppe from USP pharmaceutical-grade ketotifen hydrogen fumarate
Available Strengths	0.25 mg, 0.5 mg, 1 mg, 2 mg -- any custom strength available on request to support titration protocols
Excipients	Compounded without dyes, artificial colors, or unnecessary fillers; microcrystalline cellulose used as needed; excipient-free formulations available for highly sensitive patients -- specify on prescription
Quantity	30-day supply standard; 90-day available
Pricing	Cash pay -- contact pharmacy for current pricing
BUD / Storage	Per USP compounding standards; store at room temperature away from moisture; labeled on each preparation
Note on Ophthalmic	Ketotifen ophthalmic (Zaditor, Alaway) is FDA-approved and commercially available -- this program covers oral compounded capsules only, which have a different indication and are not interchangeable

Ordering & Contact Information

All oral ketotifen preparations require a valid prescription specifying dose and strength. Patients fill directly at our pharmacy. No prior authorization required.

How to Order

- By phone -- call (717) 846-0500; ask for the compounding pharmacist; have patient name, DOB, dose/strength, quantity, and any excipient restrictions ready
- By fax -- send prescription to (717) 845-8767; specify strength (e.g., 0.25 mg, 0.5 mg, 1 mg), quantity, and any excipient-free requirement
- E-prescribe -- select 'Compound' as medication type; enter 'Ketotifen [dose] mg capsules -- oral compounded' in the Sig/Comments field; note excipient-free if required

The Medicine Shoppe 1698 S Queen St · York, PA 17403	Phone: (717) 846-0500 Fax: (717) 845-8767

For educational purposes only -- not medical advice. Prescription required. Individual results may vary.